{"url_path":"/sec/cbio/8-k/2026-07-15/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-048347-index.html","accession_number":"0001628280-26-048347","cik":"0001253689","ticker":"CBIO","issuer_name":"CRESCENT BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1253689/0001628280-26-048347-index.html","primary_entity_key":"0001253689","primary_entity_name":"CRESCENT BIOPHARMA, INC."},"word_count":303,"has_tables":true,"body_markdown":"cbio-20260714\n0001253689false00012536892026-07-142026-07-14\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n________________________________________________________________________________________________\n\nFORM 8-K\n\n________________________________________________________________________________________________\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d)\n\nof the Securities Exchange Act of 1934\n\nDate of report (Date of earliest event reported): July 14, 2026\n\n________________________________________________________________________________________________\n\nCrescent Biopharma, Inc.\n\n(Exact Name of Registrant as Specified in Charter)\n\n________________________________________________________________________________________________\n\nCayman Islands\n001-36177\n06-1686563\n\n(State or Other Jurisdiction\nof Incorporation)(Commission\nFile Number)(IRS Employer\nIdentification No.)\n\n300 Fifth Avenue\n\nWaltham, MA\n\n02451\n\n(Address of Principal Executive Offices)(Zip Code)\n\nRegistrant’s telephone number, including area code: (617) 430-5595\n\nNot applicable\n\n(Former Name or Former Address, if Changed Since Last Report)\n\n________________________________________________________________________________________________\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\noWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\noSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\noPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\noPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading symbol(s)Name of each exchange on which registered\n\nOrdinary Shares, $0.001 par value per shareCBIO\nThe Nasdaq Capital Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\nEmerging growth company o\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o"}